American Journal of Cardiology
Volume 96, Issue 6 , Pages 810-814, 15 September 2005

Effects of Pomegranate Juice Consumption on Myocardial Perfusion in Patients With Coronary Heart Disease

  • Michael D. Sumner, PhD

      Affiliations

    • The Preventive Medicine Research Institute, Sausalito, California
  • ,
  • Melanie Elliott-Eller, RN, MSN

      Affiliations

    • The Preventive Medicine Research Institute, Sausalito, California
  • ,
  • Gerdi Weidner, PhD

      Affiliations

    • The Preventive Medicine Research Institute, Sausalito, California
  • ,
  • Jennifer J. Daubenmier, PhD

      Affiliations

    • The Preventive Medicine Research Institute, Sausalito, California
  • ,
  • Mailine H. Chew, MD

      Affiliations

    • California Pacific Medical Center, San Francisco, California
  • ,
  • Ruth Marlin, MD

      Affiliations

    • The Preventive Medicine Research Institute, Sausalito, California
  • ,
  • Caren J. Raisin, RN

      Affiliations

    • The Preventive Medicine Research Institute, Sausalito, California
  • ,
  • Dean Ornish, MD

      Affiliations

    • The Preventive Medicine Research Institute, Sausalito, California
    • California Pacific Medical Center, San Francisco, California
    • School of Medicine, University of California, San Francisco, San Francisco, California
    • Corresponding Author InformationCorresponding author: Tel: 415-332-2525, ext 222; fax: 415-332-2588.

Received 28 December 2004; received in revised form 11 May 2005; accepted 11 May 2005. published online 04 August 2005.

Pomegranate juice contains antioxidants such as soluble polyphenols, tannins, and anthocyanins and may have antiatherosclerotic properties. However, no study has investigated the effects of pomegranate juice on patients who have ischemic coronary heart disease (CHD). We investigated whether daily consumption of pomegranate juice for 3 months would affect myocardial perfusion in 45 patients who had CHD and myocardial ischemia in a randomized, placebo-controlled, double-blind study. Patients were randomly assigned into 1 of 2 groups: a pomegranate juice group (240 ml/day) or a placebo group that drank a beverage of similar caloric content, amount, flavor, and color. Participants underwent electrocardiographic-gated myocardial perfusion single-photon emission computed tomographic technetium-99m tetrofosmin scintigraphy at rest and during stress at baseline and 3 months. Visual scoring of images using standardized segmentation and nomenclature (17 segments, scale 0 to 4) was performed by a blinded independent nuclear cardiologist. To assess the amount of inducible ischemia, the summed difference score (SDS) was calculated by subtracting the summed score at rest from the summed stress score. The experimental and control groups showed similar levels of stress-induced ischemia (SDS) at baseline (p >0.05). After 3 months, the extent of stress-induced ischemia decreased in the pomegranate group (SDS −0.8 ± 2.7) but increased in the control group (SDS 1.2 ± 3.1, p <0.05). This benefit was observed without changes in cardiac medications, blood sugar, hemoglobin A1c, weight, or blood pressure in either group. In conclusion, daily consumption of pomegranate juice may improve stress-induced myocardial ischemia in patients who have CHD.

 

 This study was supported by a grant from the Resnick Foundation, Los Angeles, California, to the Preventive Medicine Research Institute, which also provided the pomegranate juice. The foundation did not participate in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the report.

PII: S0002-9149(05)01027-1

doi:10.1016/j.amjcard.2005.05.026

American Journal of Cardiology
Volume 96, Issue 6 , Pages 810-814, 15 September 2005